Goodwill is attributable to the acquisition of our pharma services in July 2019. The carrying value of the intangible assets acquired was $15.6 million, with goodwill of approximately $8.3 million and identifiable intangible assets of approximately $7.3 million. In 2019, there was an adjustment to goodwill of $0.1 million. The goodwill balance at September 30, 2021 was $8.4 million. The net carrying value of the identifiable intangible assets from all acquisitions as of September 30, 2021 and December 31, 2020 are as follows:

 SCHEDULE OF IDENTIFIABLE INTANGIBLE ASSETS CARRYING VALUE

Amortization expense was approximately $1.1 million for both the three-month periods ended September 30, 2021 and 2020, respectively and approximately $3.3 million for both the nine-month periods ended September 30, 2021 and 2020, respectively. Estimated amortization expense for the next five years is as follows:

SCHEDULE OF FUTURE ESTIMATED AMORTIZATION EXPENSE 

The following table displays a roll forward of the carrying amount of goodwill from December 31, 2020 to September 30, 2021:

SCHEDULE OF GOODWILL CARRYING VALUE 

8. Goodwill and Other Intangible Assets

 GOODWILL AND OTHER INTANGIBLE ASSETS

Goodwill is attributable to the acquisition of the Biopharma business from CGI in July 2019. The carrying value of the intangible assets acquired was $15.6 million, with goodwill of approximately $8.3 million and identifiable intangible assets of approximately $7.3 million. The goodwill balance at December 31, 2020 was $8.4 million. The net carrying value of the identifiable intangible assets as of December 31, 2020 and December 31, 2019 is as follows:

SCHEDULE OF IDENTIFIABLE INTANGIBLE ASSETS CARRYING VALUE 

The following table displays a roll forward of the carrying amount of goodwill from January 1, 2019 to December 31, 2020:

SCHEDULE OF GOODWILL CARRYING VALUE 

Amortization expense was approximately $4.5 million and $4.0 million for the years ended December 31, 2020 and 2019, respectively. Estimated amortization expense for the next five years is as follows:

Schedule of Future Estimated Amortization Expense